A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders
Phase 1
Completed
- Conditions
- Advanced Hematological Disorders
- Interventions
- Drug: ORH-2014
- First Posted Date
- 2017-02-09
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Orsenix LLC
- Target Recruit Count
- 12
- Registration Number
- NCT03048344
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸MD Anderson, Houston, Texas, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath